An FDA approved injectable methotrexate (MTX), RediTrex is designed for easy handling and dosing accuracy, resulting in increased efficacy, higher patient continuation rates, and less discomfort. RediTrex treats patients with severe and active rheumatoid arthritis and polyarticular juvenile idiopathic arthritis who have difficulty tolerating or responding to oral MTX. It is also approved for the symptomatic control of severe, recalcitrant and disabling psoriasis in adults who do not respond adequately to other forms of treatment.
“RediTrex is available in eight strengths and is designed for subcutaneous injection,” said
With more than 54 million Americans living with some form of arthritis, the disease is one of the most common causes of incapacity for work in the
The other injectable MTX options available may not optimally meet the needs of a patient with arthritis. Patients are offered either a vial and syringe for self-injection or the use of an expensive auto-injector. The vial and syringe method can be difficult for a patient to handle due to limited hand dexterity. Additionally, getting the exact dose needed while preventing skin exposure to caustic MTX can be quite difficult for patients. Auto-injectors provide a better alternative to the vial and syringe, but they take away the control of the patient’s injection and can be painful to administer. They are also the most expensive MTX delivery.
For more information about RediTrex, including complete prescribing and safety data, visit www.reditrex.com.
The Company’s portfolio of FDA-approved brands include: acetadote injection (acetylcysteine), for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Omeclamox-Pak (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and associated duodenal ulcer; RediTrex (methotrexate) Injection, for the treatment of active rheumatoid arthritis, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis; Vaprisol (conivaptan) injection, to increase serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) Injection, for the treatment of certain serious bacterial infections, including nosocomial and ventilation-associated bacterial pneumonia, as well as complicated infections of the skin and skin structures.
The Company also has ongoing Phase II clinical programs evaluating its product candidates in patients with cardiomyopathy associated with Duchenne muscular dystrophy as well as patients with systemic sclerosis and respiratory disease exacerbated by aspirin.
For more information on Cumberland’s approved products, including full prescribing information, please visit the links to the individual product websites, which can be found on the company’s website at www.cumberlandpharma .com.
This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland’s current views on future events based on what it considers reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland’s business are subject to factors beyond its control, and any or a combination of these factors could have a material effect on Cumberland’s results of operations. These factors include market conditions, competition, inability of manufacturers to produce Cumberland’s products on a timely basis or failure to comply with regulations applicable to pharmaceutical manufacturers, maintenance of a sales and marketing infrastructure. effective, natural disasters, public health epidemics, and other events beyond our control, as further explained in the Company’s most recent Form 10-K and subsequent 10-Qs filed with the
Phone. : (615) 255-0068
T: (704) 641-6641
Phone. : (615) 515-4885